Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
ATLANTA, Feb. 23, 2017 -- Alimera Sciences (NASDAQ:ALIM), a leader in research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it will release its financial results for the fourth quarter and year ended December 31, 2016, after the close of the financial markets on March 1, 2017.
An accompanying conference call will be hosted by Dan Myers, Chief Executive Officer and Rick Eiswirth, President and Chief Financial Officer to discuss the results. The call will be held at 10:00 AM ET, on Thursday, March 2, 2017. Please refer to the information below for conference call dial-in information and webcast registration.
Conference Details
Conference date: Thursday, March 2, 2017, 10:00 AM ET
Conference dial-in: 877-269-7756
International dial-in: 201-689-7817
Conference Call Name: Alimera Sciences' Fourth Quarter 2016 Results Call
Webcast Registration: Click Here
Following the live call, a replay will be available on the Company's website, www.alimerasciences.com, under "Investor Relations".
About Alimera Sciences
Alimera Sciences, founded in June 2003, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Alimera’s commitment to retina specialists and their patients is manifest in its product and development portfolio designed to treat early- and late-stage diseases. For more information, please visit www.alimerasciences.com.
Contact: CG Capital 877.889.1972 [email protected]
